Literature DB >> 11103887

A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon.

M C Wolff1, J D Leander.   

Abstract

Activity at the 5-HT2A receptor versus that of the 5-HT2C receptor was studied in three behavioural paradigms. In pigeons trained to discriminate 0.32 mg/kg of 1-(2,5-diemethoxy-4-iodophenyl)-2-aminopropane (DOI) (a mixed 5-HT2A/C receptor agonist) from vehicle, quipazine (0.1-1 mg/kg) and m-chlorophenylpiperazine (mCPP) (1-3 mg/kg) substituted for DOI in a dose-related manner, and this generalization was blocked by MDL100907 (0.0001-0.01 mg/kg), a selective 5-HT2A receptor antagonist. RO60-0175 (a relatively selective 5-HT2C agonist) induced partial substitution at 3 mg/kg that was antagonized by both MDL100907 and by 3 mg/kg of SB242084, a relatively selective 5-HT2C antagonist. MK212 (a mixed 5-HT2C/A agonist) induced partial substitution that was antagonized by SB242084, but not by MDL100907. On a progressive ratio 5 operant schedule (PR5) for food reinforcement, DOI, quipazine, mCPP, MK212 and R060-0175 decreased the break point; mCPP, DOI, MK212 and quipazine also induced vomiting. Although MDL100907 antagonized both the reductions of break point and vomiting, SB242084 only partially attenuated the decrease in break point observed with MK212 and DOI, and was unable to eliminate vomiting. Thus pharmacological activity at the 5-HT2A receptor can be behaviourally distinguished from pharmacological activity at the 5-HT2C receptor in the pigeon. Furthermore, the decrease in the break point of a PR5 schedule induced by 5-HT2C receptor agonists may be related to decreased appetite, whereas that induced by 5-HT2A receptor agonists may be due to unrelated factors, such as emesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103887     DOI: 10.1097/00008877-200008000-00001

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  9 in total

1.  Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo.

Authors:  Martilias Farrell; Sharon Rosenzweig-Lipson; Ellen Walker
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

2.  Functional characteristics of serotonin 5-HT2A and 5-HT2C receptors in the brain and the expression of the 5-HT2A and 5-HT2C receptor genes in aggressive and non-aggressive rats.

Authors:  N K Popova; V S Naumenko; R V Kozhemyakina; I Z Plyusnina
Journal:  Neurosci Behav Physiol       Date:  2010-03-25

3.  Effects of quipazine and m-chlorophenylbiguanide (m-CPBG) on temporal differentiation: evidence for the involvement of 5-HT2A but not 5-HT3 receptors in interval timing behaviour.

Authors:  S Body; K Asgari; J F Rickard; Z Zhang; K C F Fone; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

4.  Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule.

Authors:  G Bezzina; S Body; T H C Cheung; C L Hampson; C M Bradshaw; J C Glennon; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2014-08-19       Impact factor: 4.530

5.  Pharmacological Modulation of 5-HT2C Receptor Activity Produces Bidirectional Changes in Locomotor Activity, Responding for a Conditioned Reinforcer, and Mesolimbic DA Release in C57BL/6 Mice.

Authors:  Caleb J Browne; Xiaodong Ji; Guy A Higgins; Paul J Fletcher; Colin Harvey-Lewis
Journal:  Neuropsychopharmacology       Date:  2017-06-13       Impact factor: 7.853

6.  Decreased Incentive Motivation Following Knockout or Acute Blockade of the Serotonin Transporter: Role of the 5-HT2C Receptor.

Authors:  Caleb J Browne; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2016-04-29       Impact factor: 7.853

7.  Activation of the JAK-STAT pathway is necessary for desensitization of 5-HT2A receptor-stimulated phospholipase C signalling by olanzapine, clozapine and MDL 100907.

Authors:  Rakesh K Singh; Ying Dai; Jeff L Staudinger; Nancy A Muma
Journal:  Int J Neuropsychopharmacol       Date:  2008-10-31       Impact factor: 5.176

8.  A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.

Authors:  Johanna Michl; Christian Scharinger; Miriam Zauner; Siegfried Kasper; Michael Freissmuth; Harald H Sitte; Gerhard F Ecker; Lukas Pezawas
Journal:  Eur Neuropsychopharmacol       Date:  2014-07-03       Impact factor: 4.600

9.  In vivo Schild regression analyses using nonselective 5-HT2C receptor antagonists in a rat operant behavioral assay.

Authors:  Ellen A Walker; Edward K Brown; Steven N Sterious
Journal:  Psychopharmacology (Berl)       Date:  2007-04-01       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.